Dysregulacja poziomu metylotransferaz argininy w patogenezie chorób nowotworowych
References
- Alam H., Gu B., Lee M.G.: Histone methylation modifiers in cellular signaling pathways. Cell. Mol. Life Sci., 2015; 72: 4577–4592
- Amano Y., Matsubara D., Yoshimoto T., Tamura T., Nishino H., Mori Y., Niki T.: Expression of protein arginine methyltransferase-5 in oral squamous cell carcinoma and its significance in epithelial-to-mesenchymal transition. Pathol. Int., 2018; 68: 359–366
- Baldwin R.M., Bejide M., Trinkle-Mulcahy L., Côté J.: Identification of the PRMT1v1 and PRMT1v2 specific interactomes by quantitative mass spectrometry in breast cancer cells. Proteomics, 2015; 15: 2187–2197
- Baldwin R.M., Haghandish N., Daneshmand M., Amin S., Paris G., Falls T.J., Bell J.C., Islam S., Côté J.: Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget, 2015; 6: 3013–3032
- Banasavadi-Siddegowda Y.K., Welker A.M., An M., Yang X., Zhou W., Shi G., Imitola J., Li C., Hsu S., Wang J., Phelps M., Zhang J., Beattie C.E., Baiocchi R., Kaur B.: PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncol., 2018; 20: 753–763
- Bedford M.T.: The family of protein arginine methyltransferases. The Enzymes, 2006; 24: 31–50
- Behera A.K., Kumar M., Shanmugam M.K., Bhattacharya A., Rao V.J., Bhat A., Vasudevan M., Gopinath K.S., Mohiyuddin A., Chatteriee A., Sethi G., Kundu T.K.: Functional interplay between YY1 and CARM1 promotes oral carcinogenesis. Oncotarget, 2019; 10: 3709–3724
- Brehmer D., Wu T., Mannens G., Beke L., Vinken P., Gaffney D., Sun W., Pande V., Thuring J.W., Millar H., Poggesi I., Somers I., Boeckx A., Parade M., van Heerde E. i wsp.: Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models. Cancer Res., 2017; 77: DDT02–04
- Carlson S.M., Gozani O.: Emerging technologies to map the protein methylome. J. Mol. Biol. 2014; 426: 3350–3362
- Carr S.M., Roworth A.P., Chan C., La Thangue N.B.: Post-translational control of transcription factors: Methylation ranks highly. FEBS J., 2015; 282: 4450–4465
- Castellano S., Milite C., Ragno R., Simeoni S., Mai A., Limongeli V., Novellino E., Bauer I., Brosh G., Spannhoff A., Cheng D., Bedford M.T., Sbardella G.: Design, synthesis and biological evaluation of carboxy analogues of argininę methyltransferase inhibitor 1 (AMI-1). ChemMedChem., 2010; 5: 398–414
- Cheng D., Yadav N., King R.W., Swanson M.S., Weinstein E.J., Bedford M.T.: Small molecule regulators of protein arginine methyltransferases. J. Biol. Chem., 2004; 279: 23892–23899
- Eram M.S., Shen Y., Szewczyk M., Wu H., Senisterra G., Li F., Butler K.V., Kaniskan H.Ü., Speed B.A., Dela Seña C., Dong A., Zeng H., Schapira M., Brown P.J., Arrowsmith C.H. i wsp.: A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem. Biol., 2016; 11: 772–781
- Feng Y., Xie N., Wu J., Yang C., Zheng Y.G.: Inhibitory study of protein arginine methyltransferase 1 using a fluorescent approach. Biochem. Biophys. Res. Commun., 2009; 379: 567–572
- Fulton M.D., Brown T., Zheng Y.G.: Mechanisms and inhibitors of histone arginine methylation. Chem. Rec., 2018; 18: 1792–1807
- Geng P., Zhang Y., Liu X., Zhang N., Liu Y., Liu X., Lin C., Yan X., Li Z., Wang G., Li Y., Tan J., Liu D.X., Huang B., Lu J.: Automethylation of protein arginine methyltransferase 7 and its impact on breast cancer progression. FASEB J., 2017; 31: 2287–2300
- Hadjikyriacou A., Yang Y., Espejo A., Bedford M.T., Clarke S.G.: Unique features of human protein arginine methyltransferase 9 (PRMT9) and its substrate RNA splicing factor SF3B2. J. Biol. Chem., 2015; 290: 16723–16743
- Haghandish N., Baldwin R.M., Morettin A., Dawit H.T., Adhikary H., Masson J.Y., Mazroui R., Trinkle-Mulcahy L., Côté J.: PRMT7 methylates eukaryotic translation initiation factor 2α and regulates its role in stress granule formation. Mol. Biol. Cell, 2019; 30: 778–793
- Han H.S., Choi D., Choi S., Koo S.H.: Roles of protein arginine methyltransferases in the control of glucose metabolism. Endocrinol. Metab., 2014; 29: 435–440
- Hernandez S., Dominko T.: Novel protein arginine methyltransferase 8 isoform is essential for cell proliferation. J. Cell Biochem., 2016; 117: 2056–2066
- Hernandez S.J., Dolivo D.M., Dominko T.: PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer. Oncol. Lett., 2017; 13: 1938–1989
- Hsu M.C., Pan M.R., Chu P.Y., Tsai Y.L., Tsai C.H., Shan Y.S., Chen L.T., Hung W.C.: Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression. Cancers, 2018; 11: 8
- Hu G., Wang X., Han Y., Wang P.: Protein arginine methyltransferase 5 promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis. EXCLI J., 2018; 17: 1157–1166
- Hu H., Qian K., Ho M.C., Zheng Y.G.: Small molecule inhibitors of protein arginine methyltransferases. Expert Opin. Investig. Drugs, 2016; 25: 335–358
- Iderzorig T., Kellen J., Osude C., Singh S., Woodman J.A., Garcia C., Puri N.: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem. Biophys. Res. Commun., 2018; 496: 770–777
- Jahan S., Davie J.R.: Protein arginine methyltransferases (PRMTs): Role in chromatin organization. Adv. Biol. Regul., 2015; 57: 173–184
- Kaniskan H.Ü., Eram M.S., Liu J., Smil D., Martini M.L., Shen Y., Santhakumar V., Brown P.J., Arrowsmith C.H., Vedadi M., Jin J.: Design and synthesis of selective, small molecule inhibitors od coactivator-associated arginine methyltransferase 1 (CARM1). Med. Chem. Commun., 2016; 7: 1793–1796
- Karkhanis V., Hu Y.J., Baiocchi R.A., Imbalzano A.N., Sif S.: Versatility of PRMT5-induced methylation in growth control and development. Trends. Biochem. Sci., 2011; 36: 633–641
- Kleinschmidt M.A., de Graaf P., van Teeffeln H.A., Timmers H.T.: Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. PLoS One, 2012; 7: e41446
- Lattouf H., Poulard C., Le Romancer M.: PRMT5 prognostic value in cancer. Oncotarget, 2019; 10: 3151–3153
- Leipold A., Heß J., Zaoui K.: Das Epigenoom. Zielstruktur für innovative Therapiekonzepte beim Kopf- und Halskarzinom. HNO, 2015; 63: 786–791
- Li M., An W., Xu L., Lin Y., Su L., Liu X.: The arginine methyl transferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLARL in human lung cancer cells. J. Exp. Clin. Cancer Res., 2019; 38: 64
- Li S., Cheng D., Zhu B., Yang Q.: The overexpression of CARM1 promotes human osteosarcoma cell proliferation through the pGSK3β/β-catenin/cyclinD1 signaling pathway. Int. J. Biol. Sci., 2017; 13: 976–984
- Li X., Wang C., Jiang H., Luo C.: A patent review of arginine methyltransferase inhibitors (2010–2018). Expert Opin. Ther. Pat., 2019; 29: 97–114
- Li Y., Zhu R., Wang W., Fu D., Hou J., Ji S., Chen B., Hu Z., Shao X., Yu X., Zhao Q., Zhang B., Du C., Bu Q., Hu C. i wsp.: Arginine methyltransferase 1 in the nucleus accumbens regulates behavioral effects of cocaine. J. Neurosci., 2015; 35: 12890–12902
- Lin H., Wang B., Yu J., Wang J., Li Q., Cao B.: Protein arginine methyl transferase 8 gene enhances the colon cancer stem cell (CSC) function by upregulating the pluripotency transcription factor. J. Cancer, 2018; 9: 1394–1402
- Litt M., Qiu Y., Huang S.: Histone arginine methylations: Their roles in chromatin dynamics and transcriptional regulation. Biosci. Rep., 2009; 29: 131–141
- Mann M., Zou Y., Chen Y., Brann D., Vadlamudi R.: PELP1 oncogenic functions involve alternative splicing via PRMT6. Mol. Oncol., 2014; 8: 389–400
- Michalak E.M., Visvader J.E.: Dysregulation of histone methyltransferases in breast cancer – opportunities for new targeted therapies? Mol. Oncol., 2016; 10: 1497–1515
- Nakai K., Xia W., Liao H.W., Saito M., Hung M.C., Yamaguchi H.: The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. Breast Cancer, 2018; 25: 74–80
- Nakakido M., Deng Z., Suzuki T., Dohmae N., Nakamura Y., Hamamoto R.: PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget, 2015; 6: 30957–30967
- Nakayama K., Szewczyk M.M., Dela Sena C., Wu H., Dong A., Zeng H., Li F., de Freitas R.F., Eram M.S., Schapira M., Baba Y., Kunitomo M., Cary D.R., Tawada M., Ohashi A. i wsp.: TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget, 2018; 9: 18480–18493
- Obianyo O., Causey C.P., Jones J.E., Thompson P.R.: Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem. Biol., 2011; 6: 1127–1135
- Pawlicka K., Perrigue P., Barciszewski J.: Epigenetyczna kontrola procesów komórkowych. Nauka, 2018; 2: 115–128
- Peng C., Wong C.C.: The story of protein arginine methylation: Characterization, regulation, and function. Expert Rev. Proteomics, 2017; 14: 157–170
- Poulard C., Corbo L., Le Romancer M.: Protein arginine methylation/demethylation and cancer. Oncotarget, 2016; 7: 67532–67550
- Prabhu L., Chen L., Wei H., Demir Ö., Safa A., Zeng L., Amaro R.E., O’Neil B.H., Zhang Z.Y., Lu T.: Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases. Mol. Biosyst., 2017; 13: 2509–2520
- Ran T., Li W., Peng B., Xie B., Lu T., Lu S., Liu W.: Virtual screening with a structure-based pharmacophore model to identify small-molecule inhibitors of CARM1. J. Chem. Inf. Model., 2019; 59: 522–534
- Ryu J.W., Kim S.K., Son M.Y., Jeon S.J., Oh J.H., Lim J.H., Cho S., Jung C.R., Hamamoto R., Kim D.S., Cho H.S.: Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget, 2017; 8: 115444–115455
- Shailesh H., Zakaria Z.Z., Baiocchi R., Sif S.: Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer. Oncotarget, 2018; 9: 36705–36718
- Shen Y., Zhong J., Liu J., Liu K., Zhao J., Xu T., Zeng T., Li Z., Chen Y., Ding W., Wen G., Zu X., Cao R.: Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36. Oncol. Rep., 2018; 39: 2604–2612
- Smith E., Zhou W., Shindiapina P., Sif S., Li C., Baiocchi R.A.: Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. Expert Opin. Ther. Targets, 2018; 22: 527–545
- Stopa N., Krebs J.E., Shechter D.: The PRMT5 arginine methyl transferase: Many roles in development, cancer and beyond. Cell Mol. Life. Sci., 2015; 72: 2041–2059
- Tewary S.K., Zheng Y.G., Ho M.C.: Protein arginine methyltransferases: Insights into the enzyme structure and mechanism at the atomic level. Cell. Mol. Life Sci., 2019; 76: 2917–2932
- Vhuiyan M., Thomas D., Hossen F., Frankel A.: Targeting protein arginine N-methyltransferases with peptide-based inhibitors: Opportunities and challenges. Future Med. Chem., 2013; 5: 2199–2206
- Wang S.M., Dowhan D.H., Muscat G.E.: Epigenetic arginine methylation in breast cancer: Emerging therapeutic strategies. J. Mol. Endocrinol., 2019; 62: R223–R237
- Wang W.J., Hsu J.M., Wang Y.N., Lee H.H., Yamaguchi H., Liao H.W., Hung M.C.: An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. Am. J. Cancer Res., 2019; 9: 180–185
- Wang Y.P., Zhou W., Wang J., Hung X., Zuo Y., Wang T.S., Gao X., Xu Y.Y., Zou S.W., Liu Y.B., Cheng J.K., Lei Q.Y.: Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol. Cell, 2016; 64: 673–687
- Webb L.M., Amici S.A., Jablonski K.A., Savardekar H., Panfil A.R., Li L., Zhou W., Peine K., Karkhanis V., Bachelder E.M., Ainslie K.M., Green P.L., Li C., Baiocchi R.A., Gueraude-Arellano M.: PRMT5-selective inhibitors suppress inflammatory T cell responses and experimental autoimmune encephalomyelitis. J. Immunol., 2017; 198:1439–1451
- Ye F., Zhang W., Ye F., Zhang W., Ye X., Jin J., Lv Z., Luo C.: Identification of selective, cell active inhibitors of protein arginine methyltransferase 5 through structure-based virtual screening and biological assays. J. Chem. Inf. Model., 2018; 58: 1066–1073
- Ye Y., Zhang B., Mao R., Zhang C., Wang Y., Xing J., Liu Y.C., Luo X., Ding H., Yang Y., Zhou B., Jiang H., Chen K., Luo C., Zheng M.: Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening. Org. Biomol. Chem., 2017; 15: 3648–3661
- Yost J.M., Korboukh I., Liu F., Gao C., Jin J.: Targets in epigenetics: Inhibiting the methyl writers of the histone code. Curr. Chem. Genomics, 2011; 5: 72–84
- Zhang B., Chen X., Ge S., Peng C., Zhang S., Chen X., Liu T., Zhang W.: Arginine methyltransferase inhibitor-1 inhibits sarcoma viability in vitro and in vivo. Oncol. Lett., 2018; 16: 2161–2166
- Zhang B., Zhang S., Zhu L., Chen X., Zhao Y., Chao L., Zhou J., Wang X., Zhang X., Ma N.: Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5. Toxicol. Appl. Pharmacol., 2017; 336: 1–7
- Zhao X., Zhou D., Liu Y., Li C., Zhao X., Li Y., Li W.: Ganoderma lucidum polysaccharide inhibits prostate cancer cell migration via the protein arginine methyltransferase 6 signaling pathway. Mol. Med. Rep., 2018; 17: 147–157
- Zhao Y., Lu Q., Li C., Wang X., Jiang L., Huang L., Wang C., Chen H.: PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation. Cell Death. Dis., 2019; 10: 359
- Zhong J., Cao R.X., Hong T., Yang J., Zu X.Y., Xiao X.H., Liu J.H., Wen G.B.: Identification and expression analysis of a novel transcript of the human PRMT2 gene resulted from alternative polyadenylation in breast cancer. Gene, 2011; 487: 1–9
- Zhong J., Cao R.X., Liu J.H., Liu Y.B., Wang J., Liu L.P., Chen Y.J., Yang J., Zhang Q.H., Wu Y., Ding W.J., Hong T., Xiao X.H., Zu X.Y., Wen G.B.: Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein. Oncogene, 2014; 33: 5546–5558
- Zhong J., Chen Y.J., Chen L., Shen Y.Y., Zhang Q.H., Yang J., Cao R.X., Zu X.Y., Wen G.B.: PRMT2β, a C-terminal splice variant of PRMT2β, inhibits the growth of breast cancer cells. Oncol. Rep., 2017, 38: 1303–1311
- Zhong X.Y., Yuan X.M., Xu Y.Y., Yin M., Yan W.W., Zou S.W., Wei L.M., Lu H.J., Wang Y.P., Lei Q.Y.: CARM1 methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancer. Cell. Rep., 2018; 24: 3207–3223
- Zhu K., Jiang C., Tao H., Liu J., Zhang H., Luo C.: Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations. Bioorg. Med. Chem. Lett., 2018; 28: 1476–1483
DOI: https://doi.org/10.5604/01.3001.0014.8521 | Journal eISSN: 1732-2693
Language: English
Page range: 272 - 282
Submitted on: Jan 8, 2020
Accepted on: Sep 11, 2020
Published on: Apr 27, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Joanna Janisiak, Patrycja Kopytko, Maciej Tarnowski, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.